Radius Health, Inc. (RDUS)

NASDAQ: RDUS · IEX Real-Time Price · USD
10.27
-0.23 (-2.19%)
At close: Jun 29, 2022 4:00 PM
10.13
-0.14 (-1.36%)
After-hours: Jun 29, 2022 6:46 PM EDT

Company Description

Radius Health, Inc., a biopharmaceutical company, focuses on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology.

The company's commercial product is TYMLOS, an abaloparatide injection for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide-SC, which is in Phase III clinical trials for the treatment of osteoporosis in men; abaloparatide-TD, a transdermal system that is in Phase III clinical trials to treat postmenopausal women with osteoporosis; Elacestrant (RAD1901), a selective estrogen receptor degrader, which is in Phase III clinical trials for the treatment of hormone-receptor positive breast cancer; and RAD011, which is in Phase II clinical trials for treatment of hyperphagia related to Prader-Willi syndrome.

The company has collaborations and license agreements with 3M Company; Ipsen Pharma SAS; Teijin Limited; Berlin-Chemie AG; Eisai Co. Ltd.; and Duke University.

Radius Health, Inc. was founded in 2003 and is headquartered in Boston, Massachusetts.

Radius Health, Inc.
Radius Health Logo
Country United States
Founded 2003
IPO Date Jun 6, 2014
Industry Biotechnology
Sector Health Care
Employees 293
CEO G. Kelly Martin

Contact Details

Address:
950 Winter St
Waltham, Massachusetts 02451-1424
United States
Phone 617 551 4000
Website radiuspharm.com

Stock Details

Ticker Symbol RDUS
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency US Dollars
CIK Code 0001428522
CUSIP Number 750469207
ISIN Number US7504692077
Employer ID 80-0145732
SIC Code 2834

Key Executives

Name Position
G. Kelly Martin Chief Executive Officer, President and Director
Danielle Holtschlag Vice President of Sales and Head of U.S. Sales Channels
Chhaya Shah Senior Vice President and Chief Business Officer
Dr. Stavros C. Manolagas Founder and Member of the Scientific Advisory Board
Dr. John Thomas Potts Jr., DSc, M.D. Founder and Member of the Scientific Advisory Board
Dr. Michael Rosenblatt M.D. Founder, Board Observer and Member of Scientific Advisory Board
Dr. John A. Katzenellenbogen Founder and Member of the Scientific Advisory Board
Mark William Conley CPA Vice President, Chief Financial Officer, Principal Accounting Officer and Treasurer
Peter A. Schwartzman Head of Corporate Finance
Ethan Holdaway Head of Investor Relations

Latest SEC Filings

Date Type Title
Jun 24, 2022 DFAN14A Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material
Jun 23, 2022 SC14D9C Written communication relating to third party tender offer
Jun 23, 2022 8-K Current report
Jun 22, 2022 8-K Current report
Jun 21, 2022 DFAN14A Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material
Jun 17, 2022 DFAN14A Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material
Jun 16, 2022 SC 13D General statement of acquisition of beneficial ownership
Jun 13, 2022 DFAN14A Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material
Jun 8, 2022 8-K Current report
Jun 7, 2022 DFAN14A Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material